Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2014 - 2026)

Avalo Therapeutics has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $99.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 27.89% year-over-year to $99.9 million; the trailing twelve-month figure through Mar 2026 stood at $468.0 million (down 5.64% YoY), and the FY2025 full-year result was $116.5 million, down 22.74% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $99.9 million, down from $116.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $150.7 million in Q4 2024, with the low at $21.0 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $80.1 million across 5 years, with a median of $98.5 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 61.67% — and 2024, when it surged 618.01%.
• Avalo Therapeutics' Liabilities and Shareholders Equity stood at $33.4 million in 2022, then sank by 37.08% to $21.0 million in 2023, then surged by 618.01% to $150.7 million in 2024, then slipped by 22.74% to $116.5 million in 2025, then fell by 14.23% to $99.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $99.9 million (Q1 2026), $116.5 million (Q4 2025), and $125.1 million (Q3 2025), per Business Quant data.